| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| XCUR-17 | XCUR-17 | Phase 1 Clinical | Exicure Inc | Psoriasis | Details |
| PN-881 | PN-881 | Phase 1 Clinical | Protagonist Therapeutics Inc | Dermatitis; Psoriasis | Details |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Brodalumab | AMG-827; KHK-4827; IL-17R mAb; MEDI-6365 | Approved | Amgen Inc | Siliq, Lumicef, Kyntheum, 立美芙 | Japan | Psoriasis; Arthritis, Psoriatic | Kyowa Kirin Co Ltd | 2016-07-04 | Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Axial Spondyloarthritis; Brain Neoplasms; Breast Neoplasms; Colonic Neoplasms; Crohn Disease; Esophageal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Hidradenitis Suppurativa; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Mouth Neoplasms; Non-radiographic axial spondyloarthritis; Palmoplantar pustulosis; Pancreatic Neoplasms; Plaque psoriasis; Prostatic Neoplasms; Psoriasis; Pustular psoriasis; Rectal Neoplasms; Scleroderma, Systemic; Skin Neoplasms; Solid tumours; Spondylitis, Ankylosing; Stomach Neoplasms; Testicular Neoplasms; Thyroid Neoplasms | Details |